Suppr超能文献

选择性雌激素受体调节剂(SERM)对治疗男性性腺功能减退是否安全有效?

Are SERMs safe and effective for the treatment of hypogonadism in men?

作者信息

Joseph Tina, Gibbs Lawrence M, Pham Kim

机构信息

Methodist Charlton Family Medicine Residency, Dallas, TX.

出版信息

J Fam Pract. 2022 Jan;71(1):E18-E21. doi: 10.12788/jfp.0342.

Abstract

YES. For both normal-weight and obese men with low testosterone levels and hypogonadal symptoms, selective estrogen receptor modulators (SERMs), such as clomiphene citrate (CC) and enclomiphene citrate (EC), appear to be effective and safe for improving serum testosterone levels (strength of recommendation [SOR]: C, disease-oriented outcomes from randomized controlled trials [RCTs] and cohort studies). Studies also show that symptom improvement is comparable to that with exogenous testosterone replacement and similar to eugonadal men (SOR: B, patient-oriented outcomes from retrospective cohort studies).

摘要

是的。对于睾酮水平低且有性腺功能减退症状的正常体重和肥胖男性,选择性雌激素受体调节剂(SERM),如枸橼酸氯米芬(CC)和枸橼酸恩杂鲁胺(EC),在提高血清睾酮水平方面似乎是有效且安全的(推荐强度[SOR]:C,来自随机对照试验[RCT]和队列研究的以疾病为导向的结果)。研究还表明,症状改善与外源性睾酮替代治疗相当,且与性腺功能正常的男性相似(SOR:B,来自回顾性队列研究的以患者为导向的结果)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验